Antibody Therapeutics Xchange - San Francisco - 2024 - hubXchange

Loading

Registration

37 North Fireplace Side

30 mins
- Bi/Multispecifics
- Emerging Technologies
- Formats & Scaffolds
- Lead Identification & Optimization
- Target Selection

Opening Address & Keynote Presentation: The fastest route to antibodies against challenging targets

Sierra B

30 mins
- Bi/Multispecifics
- Emerging Technologies
- Formats & Scaffolds
- Lead Identification & Optimization
- Target Selection
Francisco Ylera, R&D Team Leader, New Technologies - Bio-Rad

Target Selection

Technologies to identify targets with optimal therapeutic windows.

Monterey

50 mins
- Target Selection
Remi-Martin Laberge, Co-founder, SVP and Head of Research - Arda Therapeutics
Lead Identification & Optimization

Novel approaches in antibody lead identification & optimization

Muir Woods

50 mins
- Lead Identification & Optimization
Amir Porat, Associate Director, Protein Sciences - Prothena Corporation
Bi/Multispecifics

Bi/tri-specific strategies for cell engagers and other therapeutic applications

Mendocino

50 mins
- Bi/Multispecifics
Lu Shan, Senior Director, Antibody Discovery and Protein Engineering - Alector
Formats & Scaffolds

Challenges of using single domain antibodies as new modalities of multifunctional biologics

Sonoma

50 mins
- Formats & Scaffolds
Shaun Lippow, Head of Biologics - Remunix, Inc.

1-2-1 Meetings / Networking Break

1-2-1 Meetings (Sierra A) / Networking Break (37 North Fireplace Side)

30 mins
- Bi/Multispecifics
- Emerging Technologies
- Formats & Scaffolds
- Lead Identification & Optimization
- Target Selection

1-2-1 Meetings / Networking Break

1-2-1 Meetings (Sierra A) / Networking Break (37 North Fireplace Side)

30 mins
- Bi/Multispecifics
- Emerging Technologies
- Formats & Scaffolds
- Lead Identification & Optimization
- Target Selection

Morning Refreshments

37 North Fireplace Side

10 mins
- Bi/Multispecifics
- Emerging Technologies
- Formats & Scaffolds
- Lead Identification & Optimization
- Target Selection

Target Selection

Lead Identification & Optimization topic: Early immunogenicity risk assessment and functional testing of biotherapeutics

Monterey

60 mins
- Target Selection
Sofie Pattyn, Chief Technology Officer & Founder - ImmunXperts
Lead Identification & Optimization

What is the perfect workflow for generating antibody drug candidates?

Muir Woods

60 mins
- Lead Identification & Optimization
Francisco Ylera, R&D Team Leader, New Technologies - Bio-Rad
Emerging Technologies

The battle of biologics modalities

Executive Boardroom

60 mins
- Emerging Technologies
Jane Seagal, Vice President, Antibody Discovery - Ablexis and AlivaMab Biologics
Bi/Multispecifics

Emerging Technologies Topic: Antibody Selection for complex membrane targets

Mendocino

60 mins
- Bi/Multispecifics
Ernest Smith, Senior Vice President Research & CSO - Vaccinex

Networking Lunch

Courtyard

60 mins
- Bi/Multispecifics
- Emerging Technologies
- Formats & Scaffolds
- Lead Identification & Optimization
- Target Selection

Spotlight Presentation: Engineering Unique Properties in Next-Gen Antibody Therapies

Sierra B

25 mins
- Bi/Multispecifics
- Emerging Technologies
- Formats & Scaffolds
- Lead Identification & Optimization
- Target Selection
Jordon Wang, Chief Operating Officer - Avantgen

1-2-1 Meetings / Networking Break

1-2-1 Meetings (Sierra A) / Networking Break (37 North Fireplace Side)

30 mins
- Bi/Multispecifics
- Emerging Technologies
- Formats & Scaffolds
- Lead Identification & Optimization
- Target Selection

1-2-1 Meetings / Networking Break

1-2-1 Meetings (Sierra A) / Networking Break (37 North Fireplace Side)

30 mins
- Bi/Multispecifics
- Emerging Technologies
- Formats & Scaffolds
- Lead Identification & Optimization
- Target Selection

Spotlight Presentation: Turbocharge your antibody discovery with AbTheneum

Sierra B

25 mins
- Bi/Multispecifics
- Emerging Technologies
- Formats & Scaffolds
- Lead Identification & Optimization
- Target Selection
Allison Schulkins, Chief Operating Officer - Single Cell Technology

1-2-1 Meetings / Networking Break

37 North Fireplace Side

30 mins
- Bi/Multispecifics
- Emerging Technologies
- Formats & Scaffolds
- Lead Identification & Optimization
- Target Selection

Emerging Technologies

Poster Presentation: Cutting through the hype: Real-world applications of AI in antibody discovery and engineering

Sierra B

30 mins
- Emerging Technologies
Barry Duplantis, Director of Global Business Development - Ailux Biologics (XtalPi)
Target Selection

Poster Presentation: Strategies to amplify the therapeutic potential of rabbit-derived antibodies

Monterey

30 mins
- Target Selection
Andra Li, Scientific Director - ImmunoPrecise Antibodies Canada Ltd.
Lead Identification & Optimization

Poster Presentation: Rapid Generation of Bispecific Antibodies for High Throughput Screening with SpyLock Technology

Muir Woods

30 mins
- Lead Identification & Optimization
Birthe Jessen-Park, Technical Sales Specialist Custom Antibodies - Bio-Rad

Target Selection

Considerations and challenges guiding target selection in the development of antibody-based therapeutics for cancer

Monterey

50 mins
- Target Selection
Adrian Grzybowski, Chief Scientific Officer - AnuBio
Formats & Scaffolds

Current challenges in design of bispecific/ chimeric antigen receptors for solid tumours

Sonoma

50 mins
- Formats & Scaffolds
Gunasekaran Kannan, Senior Vice President - Nutcracker Therapeutics
Bi/Multispecifics

Developing therapies to target multiple immune pathways

Mendocino

50 mins
- Bi/Multispecifics
Narayan Sastri Palla, Principal Scientist - TrueBinding
Emerging Technologies

What is the optimum human CDR-H3 repertoire for antibody discovery?

Executive Boardroom

50 mins
- Emerging Technologies
Hai Tran, Associate Director - EpiBiologics

Evening Drinks Reception

Courtyard

60 mins
- Bi/Multispecifics
- Emerging Technologies
- Formats & Scaffolds
- Lead Identification & Optimization
- Target Selection